Heute ist #Welthirntumortag. Allein in 🇩🇪 erkranken jährl. mehr als 7.000 Menschen daran. Die Studie PRIMA-CNS Uniklinik Freiburg will 2 bestehende Therapieansätze bei #Hirntumoren miteinander vergleichen, um neuen Standard in Patientenversorgung zu erreichen. ow.ly/qyPA50F1QD0

Internationale #Studie unter Leitung der Uniklinik Freiburg mit 3,1 Mio. € gefördert. Diese soll Heilungsaussichten bei aggressiven #Lymphomen im #Gehirn verbessern, welche überwiegend bei älteren Personen auftreten und unbehandelt innerhalb von wenigen Monaten zum Tod führen.

A great collaboration in EU is going on for a large randomized trial for treatment of CNS lymphoma in the elderly! Women in Lymphoma - [email protected] WiLing Wednesday on treatment of elderly PCNS and side effects of radiation #lymsm @Schorb_Liz

ASCT for lymphoma #ASH22 part 1: -feasible in selected elderly patients with newly diagnosed primary CNS lymphoma with survival rates comparable to those of younger cohorts -non-relapse mortality remains a major challenge in this vulnerable population ash.confex.com/ash/2022/webpr… /5

Tues Dec 13 #ASH2022 late breaking abstract 👏 Effects on Survival of Non-Myeloabl chemo c.f. HD-Chemo follow by HDC-ASCT As Consolidatn in #PCNSL Results of International Randomized Phase III Trial (MATRix/IELSG43) ⁦@Schorb_Liz⁩ ⁦@GILLI_1969⁩ ash.confex.com/ash/2022/webpr…

Gerald Illerhaus IELSG43 data - underscoring superiority of TT/BCNU ASCT as highly effective consolidation following MATRix remission induction. Key unmet need remains wrt early events & failure to reach ASCT; 🇩🇪 🏴󠁧󠁢󠁥󠁮󠁧󠁿 🇮🇹 OptiMATE Ph3 aiming to optimise Elisabeth Schorb Kate Cwynarski

#ASH22 Late Breaking Abstract @GILLI_1969 presents IELSG43 randomised trial: impressive data in #PCNSL for consolidation TT-based ASCT after MATRix <70y 3 year OS 86% Credit to all the investigators for addressing this important question ⁦Elisabeth Schorb⁩ #IELSG #AndresFerreri

Remarkable results and (for a change) a reaffirmed role for autoSCT in primary CNS #lymphoma.

Andrew M. Evens, DO, MBA, MSc Ajay Major, MD, MBA Really important data Andrew M. Evens, DO, MBA, MSc & great 🇺🇸 collaboration 👏 We showed similar findings and helpful to have RWE data in #PCNSL >60yrs. We ⬆️ consider TT-ASCT >70yrs & exciting to hear MARTA trial Elisabeth Schorb Gerald Illerhaus #ASH2022 pubmed.ncbi.nlm.nih.gov/32232989/

Potentially practice-changing Ph3 RCT for MATRix-eligible pts with newly dx PCNSL. Great to collaborate with 🇩🇪 colleagues Elisabeth Schorb Gerald Illerhaus Science and Innovation at Cancer Research UK Stand Up To Cancer UK funded incl translational science Jessica Okosun & imaging NIHR Nottingham BRC Imaging ResearchNUH

6/10 invited manuscript by Women in Lymphoma - [email protected] for #HematologicalOncology International Conference on Malignant Lymphoma "Central nervous system lymphomas—Assessment and treatment and prevention of central nervous system relapse" onlinelibrary.wiley.com/doi/10.1002/ho… #lymsm #lymphoma #CellularTherapy Lymphoma Australia

Delighted to share the results of our MARTA trial, just published in The Lancet Haematology. A collaborative effort of the German PCNSL Study Group. We are deeply thankful for the support of all collaborators and Else Kröner-Fresenius-Stiftung authors.elsevier.com/a/1iW3b_rV3GEO…

Elisabeth Schorb The Lancet Haematology Else Kröner-Fresenius-Stiftung & our commentary - pleasure working with Beth Phillips & a credit to Elisabeth Schorb Gerald Illerhaus & all co-authors The Lancet Haematology #PCNSL thelancet.com/journals/lanha…

🎧NEW podcast: Elisabeth Schorb on the MARTA phase 2 trial testing high-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma #lymsm buff.ly/4bSUzfs

Elisabeth Schorb You can read the report on the MARTA trial here buff.ly/3TgurUl Also, the linked comment by Elizabeth H Phillips & Kate Cwynarski #lymsm buff.ly/4bVp8kv

New📢Primary Central Nervous System #Lymphomas: European Hematology Association–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Covering clinical, imaging & pathological diagnosis, staging & risk assessment, tx, & algorithms for first-line & salvage treatments.

Kate Cwynarski and A Ferreri presenting the European Hematology Association - ESMO - Eur. Oncology Guidelines on primary CNS #lymphoma at #EHA2024 🧠